HCRU and costs among patients with schizophrenia switching from oral risperidone/paliperidone to once-monthly paliperidone palmitate: A VHA claims analysis

Abstract Authors: Charmi Patel, Antoine El Khoury, Ahong Huang, Li Wang, Richa Bashyal Background: Schizophrenia is associated with high health care resource utilization and treatment costs. Objective: This study compared treatment patterns, health care resource...

Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among VHA patients with schizophrenia with at least one prior hospitalization

Abstract Authors: Antoine El Khoury, Charmi Patel, Ahong Huang, Li Wang, Richa Bashyal Objective: To address gaps in the literature on healthcare resource utilization (HRU) and costs among patients with schizophrenia and prior hospitalization who transition from oral...

Health outcomes among patients diagnosed with schizophrenia in the US Veterans Health Administration population who transitioned from once-monthly to once-every-3-month paliperidone palmitate: An observational retrospective analysis

Abstract Authors: Charmi Patel, Antoine El Khoury, Ahong Huang, Li Wang, Onur Baser, Kruti Joshi Introduction: There is limited literature on treatment patterns, healthcare resource utilization (HRU), and costs among patients who transition from once-monthly...